BIIB - Biogen - Stock Forecast

Healthcare - Sector
Coverage Profile Stock analysts Price Targets & Ratings Chart Insider Trading

BIIB is currently covered by 27 analysts with an average price target of $284.26. This is a potential upside of $59.05 (26.22%) from yesterday's end of day stock price of $225.21.

Biogen's activity chart (see below) currently has 791 price targets and 677 ratings on display. The stock rating distribution of BIIB is 77.92% BUY and 22.08% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 66.77% with an average time for these price targets to be met of 233.11 days.

Highest price target for BIIB is $373, Lowest price target is $200, average price target is $284.26.

Most recent stock forecast was given by ROBYN KARNAUSKAS from TRUIST on 16-May-2024. First documented stock forecast 09-Sep-2010.


Biogen  is focused on the discovery, development, manufacturing innovative therapies for the treatment of neurological and neurodegenerative diseases.


Biogen offers a diverse portfolio of therapies targeting various neurological conditions.

For multiple sclerosis (MS), the company provides products such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA, which aim to manage and alleviate the symptoms of this chronic autoimmune disease.

Biogen’s SPINRAZA is a groundbreaking therapy for spinal muscular atrophy (SMA), a genetic neuromuscular disorder that affects muscle movement. The company’s innovative treatment, ADUHELM, addresses Alzheimer’s disease, a progressive neurodegenerative disorder characterized by cognitive decline.

In addition to MS, SMA, and Alzheimer’s disease, Biogen’s product lineup encompasses various therapeutic areas. The company offers FUMADERM to treat plaque psoriasis, a chronic skin condition. BENEPALI, IMRALDI, and FLIXABI are biosimilars developed by Biogen, referencing well-established therapies for conditions like rheumatoid arthritis and certain types of cancer.

Furthermore, Biogen delivers therapies like RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and glofitamab to address a range of disorders, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, and other immunological and neurovascular conditions.


Biogen’s headquarters are located in Cambridge, Massachusetts, since it was founded in 1978.

Currently out of the existing stock ratings of BIIB, 120 are a BUY (77.92%), 34 are a HOLD (22.08%).

Analyst name


Current price target

Potential Upside

Previous price target


Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score



$112.31 (49.33%)


6 days ago

17/35 (48.57%)

$109.96 (47.80%)




$42.31 (18.58%)


23 days ago

24/37 (64.86%)

$61.1 (29.25%)




$-27.69 (-12.16%)


27 days ago

20/23 (86.96%)

$-2.46 (-1.22%)




$66.31 (29.12%)


28 days ago

7/22 (31.82%)

$92.01 (45.55%)




$-13.69 (-6.01%)


1 months 5 days ago

4/15 (26.67%)

$21.84 (11.37%)


Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is BIIB (Biogen) average time for price targets to be met?

On average it took 233.11 days on average for the stock forecasts to be realized with a an average price target met ratio 66.77

Which analyst has the current highest performing score on BIIB (Biogen) with a proven track record?


Which analyst has the most public recommendations on BIIB (Biogen)?

Marc Goodman has 9 price targets and 7 ratings on BIIB

Which analyst is the currently most bullish on BIIB (Biogen)?

Ravi Mehrotra with highest potential upside - $242.99

Which analyst is the currently most reserved on BIIB (Biogen)?

Tim Anderson with lowest potential downside - -$40.01

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?